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Background and Objectives: Inappropriate use of analgesic drugs
has become increasingly pervasive over the past decade. Currently,
drug abuse potential is primarily assessed post-marketing; no
validated tools are available to assess this potential in phase II and
III clinical trials. This paper describes the development and feasibility
testing of a Misuse, Abuse, and Diversion Drug Event Reporting
System (MADDERS), which aims to identify potentially abuse-
related events and classify them according to a recently developed
classification scheme, allowing the quantification of these events in
clinical trials.
Methods: The system was initially conceived and designed with
input from experts and patients, followed by field-testing to assess its
feasibility and content validity in both completed and ongoing
clinical trials.
Results: The results suggest that MADDERS is a feasible system
with initial validity. It showed higher rates of the triggering events in
subjects taking medications with known abuse potential than in
patients taking medications without abuse potential. Additionally,
experts agreed on the classification of most abuse-related events in
MADDERS.
Discussion and Conclusions: MADDERS is a new systematic
approach to collect information on potentially abuse-related events in
clinical trials and classify them. The system has demonstrated
feasibility for implementation. Additional research is ongoing to
further evaluate its validity.
Scientific Significance: Currently, there are no validated tools to
assess drug abuse potential during clinical trials. Because of its ease
of implementation, its systematic approach, and its preliminary
validation results, MADDERS could provide such a tool for clinical
trials. (Am J Addict 2016;25:641–651).
INTRODUCTION
Prescription drug abuse, a major public health problem in
the United States, is manifested by increased incidence of
addiction, emergency department visits, fatal and nonfatal
overdoses, accidental pediatric ingestion, injection drug
diseases (including HIV and hepatitis), and significant societal
costs.1–5
Abuse has been defined as any intentional, nontherapeutic
use of a drug product or other substance, even once, for the
purpose of achieving a desirable psychological or physiologi-
cal effect.6 For the purpose of this paper, the term “abuse-
related events” refers to a broader set of behaviors, including
behaviors that are confused with abuse (eg, misuse or suicide-
related medication ingestion), important consequences of
abuse (eg, overdose), and important concomitants of abuse
(eg, tampering), and events that form part of the broader
assessment of the abuse potential of a drug (eg, withdrawal).
According to European and Unite States regulatory guide-
lines for assessing the abuse potential of a drug during its
development, sponsors should make every effort to set criteria
for assessing abuse, collect complete abuse-related data, and
determine the potential risk of abuse-related events.7,8
Traditionally, clinical trials have assessed the abuse potential
of a drug by capturing reported adverse events (AEs). To
capture these events, researchers have used various assessment
tools, including algorithms based on AE coding dictionaries
(eg, StandardizedMedical Dictionary for RegulatoryActivities
[MedDRA] Queries [SMQ] for substance abuse). These tools,
however, fail to identify all relevant types of AEs and do not
account for drug accountability discrepancies, that is, differ-
ences in the expected amounts of unused medication in a
subject’s possession at specified periods in a clinical trial.
Moreover, the tools lack standardized terminology and have not
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been validated. Indeed, in a comprehensive review, Smith at el
al.9 concluded that classification of abuse-related events in
clinical trials by currently available methods is inadequate and
that more-reliable, validated assessments of such events are
needed.
In recognition of the need for standardized terminology as a
first step in developing a standardized approach to assessment
of abuse-related events in clinical trials, the Analgesic,
Anesthetic, and Addiction Clinical Trials, Translations,
Innovations, Opportunities, and Networks (ACTTION)
public-private partnership convened an expert panel to
identify the relevant terms and the most appropriate
definitions.6 The terms and definitions developed by that
group were organized into a classification scheme that
included six mutually exclusive categories (misuse, abuse,
suicide-related, therapeutic error, none of the above, and
unknown) plus five supplemental designators (tampering,
withdrawal, addiction-related, diversion, and overdose)
(Figure 1, adopted with permission from Smith et al.6).
The ACTTION classification scheme allows for the use of a
common terminology among clinical researchers and serves as
the foundation for the reliable and accurate classification of
abuse-related events. However, the use of such a classification
scheme in an actual clinical trial to assess a drug’s potential for
abuse requires a reliable, systematic, and validated approach
that allows the quantification of a drug’s potential for abuse or
misuse. We therefore developed MADDERS as an extension
of the ACTTION scheme. The MADDERS was designed to
identify potentially abuse-related events and to promote the
collection of the needed information for utilizing the
ACTTION classification scheme in clinical trials.
METHODS
Overview of MADDERS Development Program
MADDERS was designed as an extension of ACTTION
and other existing classification systems for capturing AEs in
clinical trials in the arena of prescription drug abuse; it is not
intended to be a diagnostic instrument, a scale, or a measure of
patient-reported outcomes. The process of MADDERS begins
with identifying triggering events, that is, AEs that suggest
potential abuse and would trigger the implementation of
MADDERS in a clinical trial. In addition to these AEs,
FIGURE 1. Analgesic, Anesthetic, and Addiction Clinical Trials, Translations, Innovations, Opportunities, and Networks (ACTTION) classification
scheme for misuse, abuse, and related events. (adapted from Smith et al.9; permission obtained from the publisher). For each event, one event
category would be chosen; the severity of the event, the dosage form, and themethod of administration would be identified; and any supplemental
designations providing further information about the event would be selected.Dosage forms: OS: solid designed to be swallowed intact; TM: solid
designed for administration through oral mucosa (eg, buccal, sublingual); TD: solid designed for transdermal administration (eg, patch); SS:
semisolid designed for transdermal administration (eg, gel, ointment, lotion, cream); OL: liquid designed for administration by swallowing (eg,
solutions, suspensions, emulsions); NL: liquid designed for administration intranasally (eg, metered sprays); NA: aerosol designed for
administration intranasally; PI: inhalants or sprays designed for pulmonary administration; UNK: unknown. Administration method: Oral;
Sublingual; Nasal insufflation (ie, “snorted”); Vaporized and inhaled; Injected; Unknown. Event categories: Misuse-event indicator: Any
intentional therapeutic use of a drug product in an inappropriate way. Misuse specifically excludes events that meet the definition of an Abuse-
event indicator. Abuse-event indicator: Any intentional, nontherapeutic use of a drug product or substance, even once, for the purpose of
achieving a desirable psychological or physiological effect. Suicide-related event: A self-injurious or potentially self-injurious behavior associated
with at least some intent to die or that resulted in death. Evidence that the individual intended to kill him/herself, at least to some degree, can be
explicit or inferred from the behavior or circumstance. A suicide attempt may or may not result in actual injury (adapted from Posner et al.10).
Therapeutic error: A mistake in a therapeutic regimen. None of the above: Sufficient information exists to determine that none of the previous
categories apply. Unknown: Insufficient information exists to determine which category applies. Definitions of supplemental designations:
Tampering: The inappropriate manipulation of a drug product.Withdrawal: Symptoms or signs due to the decline in blood concentration of a drug
substance (eg, after dose reduction, at the end of a dosing interval, after discontinuing treatment) or due to the administration of an antagonist.
Addiction-related indicator: Behavioral, cognitive, and physiological phenomena that may develop after exposure to a substance (typically on a
repeated basis), which may include a strong desire to take the drug, difficulties in controlling drug use, persistent drug use despite harmful
consequences, intractable and distracting thoughts about the drug, or placing a higher priority on drug use than other activities and obligations.
Diversion: Any intentional act that results in transferring a drug product from lawful to unlawful distribution or possession. Diversion can occur with
all categories except Therapeutic Error. Overdose: Any act that results in drug exposure exceeding that which is generally recommended or
medically accepted.
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triggering events also include drug accountability discrep-
ancies, which are differences in the expected amounts of
unused medication in a subject’s possession at specified
periods in a clinical trial.
Following events identification, another major component
of the system is training investigators and other site personnel
on all aspects of MADDERS (see Table 1 for some training
examples used). For this purpose, a web-based training
program was developed.
Our development and initial evaluation of MADDERS
included four steps: (i) systematic identification of triggering
events; (ii) validation of the list of triggering events; (iii)
development of the MADDERS form and cognitive debrief
with key stakeholders; and (iv) feasibility assessment of the
MADDERS classification process.
The first step in MADDERS is the identification of
triggering events. The research team identified a comprehen-
sive list of over 200 unique AE terms related to inappropriate
medication use from (i) regulatory guidance documents (U.S.
Food and Drug Administration [FDA] and Canadian Health
Authority); (ii) SMQ terms for drug dependence; (iii) World
Health Organization pharmacovigilance reports on drugs of
abuse; (iv) Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IV), listings of signs and
symptoms of drug abuse; (v) scientific literature on symptoms
of drug abuse and withdrawal; and (vi) databases from
cannabinoid and opioid clinical trials. This extended list was
reviewed and reduced to approximately 80 terms; items that
were unlikely to predict abuse or that were redundant were
removed. MedDRA experts who were involved in MedDRA
development then reviewed this list. They mapped any non-
MedDRA terms to MedDRA Preferred Terms; combined
related items into single terms (eg, “drug dependence,” “drug
dependence antepartum,” and “drug dependence postpartum”
were collapsed into “drug dependence”); and eliminated
duplicate entries that mapped to the same MedDRA Preferred
Term. The final list had 60 Preferred Terms (Table 2).
The research team recognized that unlike the case for AEs,
the identification of drug accountability discrepancies would
depend on the drug formulation, the methods of use (route of
administration), and the prescribed amounts. For example, in a
trial where subjects are prescribed a weekly patch, onemissing
patch might be used to trigger evaluation, whereas in a trial
where subjects are given a bottle of 120 tablets to last for
30 days, one missing tablet may be an oversensitive criterion.
Thus, the group developed a policy whereby the drug
discrepancy threshold would need to be defined a priori and
justified for each drug and each study.
The second step was to test the validity of the list of 60
triggering events in differentiating drugs with known abuse
potential (abused drugs) from drugs without known abuse
potential (nonabused drugs). We compared the number of
times the terms on our list were reported in the FDA’s Adverse
Events (FAERS) database for abused and nonabused drugs.
Data were retrieved from FAERS from 1998 (when MedDRA
coding was implemented) to August 2012.
Drugs were selected for the evaluation of validity of the
triggering AE list based on the following principles: (i) only
generic drugs were used to avoid biases that might be
introduced by brand vs. generic status; (ii) drugs of abuse from
multiple pharmacologic classes were used to avoid a list
relevant to only one class of abused drugs; (iii) non-abused
drugs were also selected from multiple pharmacologic classes
that act both centrally and peripherally; (iv) a broad range of
indications were used for both abused and non-abused drugs to
avoid bias by indication; (v) non-abused drugs that are
associated with physical dependence and withdrawal were
included in order to avoid imbalance of the AE list towards
withdrawal.
Additionally, for the statistical benefit of large sample size,
only drugs with more than 1,000 reported AEs were included
in the analysis. The representative abused drugs evaluated
were alprazolam, dextromethorphan, diazepam, hydrocodone,
methylphenidate, and oxycodone; the nonabused drugs were
duloxetine, sodium valproate, aripiprazole, and metoprolol.
To examine the utility of each AE Preferred Term in the
FAERS database, we categorized it as having positive, neutral,
or negative value by using an artificial cutoff of .1%
difference in the term’s frequency between abused and
nonabused drugs (ie, a difference of more than .1% was
classified as positive; a difference of less than .1% was
considered negative; and a difference in the range of .1 to .1
was neutral). Because this is the first-ever development of such
a system for assessing abuse potential in clinical trials, we had
no a priori thresholds, so the .1% cutoff was based on the data
at hand.
In the third step, to capture the additional information
needed to classify the triggering events according to the abuse-
related terms, definitions, and classification scheme developed
by the ACTTION panel, we designed the MADDERS form. A
key element in capturing this information is real-time (or near
real-time) interviews with subjects. These timely interviews
will allow researchers to collect the most accurate and least
biased information about the triggering event immediately
after it was identified during the clinical trial.
After discussing with three drug-abuse experts what
information was needed to classify events into each abuse-
related term, we generated our first MADDERS form
(version 1). Given the wide range of potential triggering
events, we decided that the form should be interview-guided
that will be completed by clinicians rather than subjects. The
form guides the interviewer about the information that
should to be collected, without providing exact text to read to
the subjects. (ie, structured interview). In response to the
experts’ review of the form (see next paragraph), we made
minor modifications to it.
To assess the feasibility of the interview process for
completing theMADDERS form, we asked four site clinicians
involved in recently completed analgesic clinical trials to
conduct interviews with 18 trial subjects and to complete the
MADDERS form as if this were done at the trial they had
recently completed. We collected input from both clinicians
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TABLE 1. MADDERS1 definitions and training examples of abuse-related events for ACTTION classifications
Classification and definition Training examples
Event categories
Misuse: Any intentional therapeutic use of a drug product in an
inappropriate way.
A cancer patient presents to the clinic with two vials missing. His wife
indicates that he has been using somewhat more medication than
prescribed in order to get better pain relief, which has been working
for him, but he has been increasingly tired.
Abuse: Any intentional, nontherapeutic use of a drug product or
substance, even once, for the purpose of achieving a desirable
psychological or physiological effect.
A patient in a blinded clinical trial admits saving up his study
medication during the week so he can use it at parties to “get in the
mood.” He reports no untoward medical events associated with this
use pattern.
Suicide-related: A self-injurious or potentially self-injurious
behavior associated with at least some intent to die or that
resulted in death.
A patient in a clinical trial was difficult to arouse and was taken to the
ER. Upon awakening, she indicated that her pain was increasingly
out of control and she had lost hope for a cure. She also
acknowledged being increasingly despondent and having taken all
her remaining prescribed opioid pills since she did not care whether
she lived or died.
Therapeutic error: A mistake in a therapeutic regimen. A patient in a clinical trial had one missing tablet. He reported that he
had taken two tablets instead of one by accident.
None of the above: Sufficient information exists to determine that
none of the previous categories apply.
A patient in a clinical trial reported that he was euphoric/elated due to
his diminished pain.
Unknown: Insufficient information exists to determine which
category applies.
A patient in an open-label study of opioids did not return for his
routine monthly clinic visit 1 month into the study and despite
repeated efforts could not be located for follow-up.
Supplemental designations
Tampering: Inappropriate manipulation of a drug product. A 47-year-old man with multiple myeloma in hospice was in a clinical
trial of a cannabinoid for nausea. In the course of routine
chemotherapy, he developed moderate oropharyngeal mucositis and
was unable to swallow. To prevent withdrawal and maintain pain
relief, the clinicians crushed the tablet and put it down the G-tube.
The patient was very drowsy for a few hours after the first dose but
recovered.
Withdrawal: Symptoms or signs due to the decline in blood
concentration of a drug substance.
During a routine clinic visit, a patient in a blinded clinical trial
reported that she had run out of her medications 2 weeks earlier and
that a day after running out, she felt sick, being jittery and
nauseated. This feeling lasted a few days but then returned to
normal.
Addiction-related indicator: Behavioral, cognitive, and
physiological phenomena that may develop after exposure
to a substance (typically on a repeated basis) and which may
include a strong desire to take the drug, difficulties in
controlling drug use, persistent drug use despite harmful
consequences, intractable and distracting thoughts about the
drug, or placing a higher priority on drug use than on other
activities and obligations.
A 16-year-old boy in an open-label safety study of an opioid for
chronic pain did not show up for a routine clinic visit, and the
family indicated that he had been in and out of the ER over the past
few weeks for taking too much of his medication. He had also been
missing school, and there was missing liquor in the liquor cabinet.
In recent months, he had been smoking increasing amounts of
marijuana and cigarettes and drinking with new friends.
Diversion: Any intentional act that results in transferring a drug
product from lawful to unlawful distribution or possession.
A 38-year-old woman patient had 20 tablets missing at a routine clinic
visit. Upon questioning, she acknowledged sharing the medication
with her sister, who was having terrible insomnia after the death of
her spouse.
Overdose: Any act that results in drug exposure exceeding that
which is generally recommended or medically accepted.
A 61-year-old cancer patient normally taking 4 pills twice a day took
10 one evening in order to have better pain control. He was
somnolent and dizzy for several hours, then recovered.
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and subjects about the structured interview through a paper-
based survey. The subjects were asked to answer the following
questions on a 0–10 numerical rating scale: How well did the
process work (0¼ not well at all; 10¼ extremely well)? How
much difficulty did you have understanding the questions
(0¼ no difficulty, 10¼ extreme difficulty)? How truthful
would you be in answering questions about your study
medication use (0¼ always truthful, 10¼ never truthful)?
Clinicians were asked about the feasibility of the MADDERS
form and the interview-guided process.
The fourth and final step was to evaluate the feasibility of
using the classification process in a clinical trial. We asked
three experts in prescription drug abuse who had completed
the MADDERS training to independently classify 10 mock
cases. The mock cases were presented to the experts as subject
narratives based on data that could have been captured on the
MADDERS form in an actual clinical trial.
Statistical Analysis
To assess differences in the numbers of AE events
identified in the FAERS database between abused and
nonabused drugs, we used a paired t-test. The Fleiss kappa
test was used to assess agreement between experts’
classifications of the 10 mock cases. We considered p values
significant if they were below .05.
RESULTS
During the period that the FAERS database covered (1998
to August 2012), there were 58,973 reported AEs (whether the
AE was what we defined as a triggering event or not) for
abused drugs and 51,831 for nonabused drugs (Table 2). The
mean number of events for each of the top 20 terms reported
for abused drugs (out of the list of 60 triggering events) was
significantly higher (paired t-test, p< .001) for abused drugs
(1,628, or 2.8% of total AEs) than for nonabused drugs (725, or
1.4% of total AEs). Among all 60 terms in Table 2, 19 (32%)
were considered positive terms (ie, the AE occurred more
frequently in abused than in nonabused drugs); 25 (42%) were
considered neutral; and 16 (27%) were negative (ie, the AE
occurred less frequently in abused than in nonabused drugs).
There was a significantly higher (p¼ .038) cumulative
percentage of AEs among abused drugs (68.4%) than among
nonabused drugs (41.9%). Figure 2 shows some important
distributions of these AEs. The top panel shows that among the
top 20 Preferred Terms reported for abused drugs, overdose
was the most frequent AE (5,573 reports, or 9.5% of total
AEs). The bottom panel presents the 20 AEs that demonstrated
the highest differences (in percentage) in occurrence for
abused drugs and nonabused drugs.
The results of the survey about the feasibility of the
interview-guided MADDERS form were instructive. The
subjects responded positively to the process (mean score 9.9
on 0–10 scale; 0¼ not well at all, 10¼ extremely well). They
indicated that they had little difficulty understanding the
questions (mean score .3 on 0–10 scale; 0¼ no difficulty,
10¼ extreme difficulty), with little explanation needed for
most questions. Most subjects indicated that they would
answer questions about their study medication use truthfully,
although a few indicated they might not be completely honest
(mean score1.8 on 0–10 scale; 0¼ always truthful, 10¼ never
truthful) or that others might lie about abuse and tampering.
The four site clinicians who were surveyed about the
feasibility of the MADDERS form and interview process
considered the questions on the MADDERS form clear; they
thought that the questions gathered sufficient and appropriate
information, and the clinicians reported that the subjects’
responses were accurate and honest overall.
Finally, the results for assessing the feasibility of using
MADDERS to classify triggering events in clinical trials were
highly consistent. Among the three experts in MADDERS
who classified 10 mock cases prepared according to
MADDERS forms and guidelines, there was 90% agreement
(9/10 narratives). Fleiss kappa test for agreement between the
experts’ classifications was .881 (p< .001).
DISCUSSION
We have described the development and initial feasibility
testing of MADDERS, a system that goes beyond the
ACTION classification scheme and enables researchers to
characterize abuse-related events in clinical trials. The list of
MedDRAPreferred Terms used to identify triggering events in
clinical trials has demonstrated usability, with a manageable
number of identified events. Subsequently, the differences
between the distribution of identified triggering events in
abused drugs and those in nonabused drugs was demonstrated
using the FAERS database. Experts in addiction and abuse,
site clinicians, and subjects in clinical trials supported the
content validity of MADDERS.
Identifying specific events in clinical trials requires careful,
thorough, and standardized assessment and classification. For
instance, Posner et al.10,11 have developed a method to
categorize suicidal events occurring in antidepressant clinical
trials. The strength of this suicide classification system is its
ability to comprehensively identify suicidal events while
limiting the over identification of suicidal behavior. MAD-
DERS uses a similar systematic approach to classify
potentially abuse-related events in clinical trials. It is designed
as an extension of existing systems for capturing AEs in the
arena of prescription drug abuse and is not intended to be a
diagnostic instrument, a scale, or a measure of patient-reported
outcomes. Nonetheless, additional information about the
measurement properties of MADDERS would help refine
the system and improve its effectiveness. For example, using
MADDERS in clinical trials that compare a known potentially
abused medication with a nonabused medication would help
explore the system’s criterion validity. Similarly, determining
whether the system can detect changes in inappropriate uses of
medication over time, particularly in a trial of a treatment
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known to reduce abuse, would further refine MADDERS. Our
analysis of the FAERS database demonstrates the validity of
the list of AE terms in discriminating abused prescription
drugs from nonabused ones. However, among our 60 Preferred
Terms, only about one-third differentiated the two groups.
Additional validity testing of MADDERS with data sets from
clinical trials of compounds with known abuse potential is
ongoing. Collecting additional data will allow the opportunity
to refine and optimize the triggering event identification
process. This would increase sensitivity and specificity and
will establish “normative data” that will facilitate comparison
across studies/drugs.
The system was designed to obtain more thorough
information on intent, behavior, and other contextual factors
associated with potentially abuse-related events by training
investigators to (i) play an active role in identifying triggering
events and (ii) obtain additional information from subjects via
guided interviews as soon as possible after an event occurs.
This approach provides more comprehensive information,
which is expected to lead to greater accuracy in the
classification of potential abuse-related events.
However, a few limitations are worth mentioning. First,
because MADDERS relies on subjects’ reports during an
interview with a clinician, candor might be an issue.
Nevertheless, asking always yields more information than
does failing to ask, and the standardized, systematic nature of
an interview based on theMADDERS form reduces bias in the
assessments. Second, the data we have presented demonstrate
the system’s potential feasibility and initial validity, and
additional testing in trials of drugs with known abuse liability
is ongoing to further validate MADDERS. Third, the abuse-
related data on the specialized population of subjects who have
given their consent and who are included and monitored in
clinical trials might not apply to the general population.
However, MADDERS is not intended to substitute for current
methods of assessing abuse liability. By collecting relevant
information systematically, this approach will allow the
interpretation and use of data that are already collected in
clinical trials (ie, AEs and drug accountability discrepancies)
for the assessment of the abuse potential of a drug. Fourth, in
this initial retrospective validation study, drug discrepancies
could not be assessed. Ongoing prospective studies have been
providing valuable information confirming the need for a
policy whereby the drug discrepancy threshold would be
defined a priori and justified for each drug and each study.
In the development of any drug, research on its potential
for abuse must strike a fine balance between good sensitivity
and over identification of triggering events. A lack of
sensitivity could fail to uncover potential problems with a
drug, whereas over identification of AEs could curtail, for
example, the development of an effective pain medication.
Future research is needed to refine triggering-event
identification and quantification to better balance sensitivity
and over classification.
The necessary steps in assessing abuse potential during
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pharmacology, in vitro formulation tests, preclinical studies of
abuse potential, phase I pharmacokinetic studies, and phase I
human abuse liability studies, are well established and
commonly used.12 Ironically, there are no standardized,
systematic methods for quantifying abuse-related events in
phase II and phase III clinical trials where drugs are actually
given to the target population for the target indication.9,13–16 In
their recent review on the inappropriate use of medication,
Smith et al.9 conclude that the available instruments are not
well suited for assessing the inappropriate use of medication
within clinical trials. The researchers add that further effort is
needed to develop reliable and valid instruments to conduct
such assessments. In the face of concerns about abuse of, and
addiction to, certain classes of analgesic medications (eg,
opioids), as well as opposite concerns that people with chronic
pain conditions will not receive adequate pain treatment, it is
crucial to accurately estimate the incidence of misuse, abuse,
and related events in clinical trials to properly balance the risks
and benefits of these medications. MADDERS has been
developed to systematize the collection of essential informa-
tion so that potentially abuse-related events can be classified
and their frequency assessed.
To date, the use ofMADDERS to identify triggering events
has content validity. We base this observation on literature
reviews and expert input, as well as data indicating higher
incidences of triggering events for abused drugs than for
nonabused drugs. Experts have indicated that the MADDERS
forms used are practical and content-valid for assessing abuse-
related events. Field testing has shown MADDERS to be
feasible for the experts who classified the mock cases, for trial
subjects, and for site clinicians. Based on the current results, a
refined version of MADDERS has been implemented in
multicenter trials. To our knowledge, it is the only system
currently available for classifying and quantifying abuse-
related events in clinical trials.
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its validation during discussions at an ACTTION meeting,
“Recommendations for Quantifying Abuse-Related Events in
Clinical Trials,” held June 27–28, 2013, inWashington, DC. In
addition, we thank the following experts for content review and
adjudications: Drs. Roger Weiss (Harvard Medical School),
Richard Dart (Rocky Mountain Poison and Drug Center),
Jennifer Sharpe Potter (UT Health Science Center San
Antonio), and Ajay Wasan (University of Pittsburg Medical
School). Review and input from Drs. Gil Sperings (MedVadis),
Steven Wright (Analgesic Solutions), and Steve Passik
(Vanderbilt Medical School) are also gratefully acknowl-
edged. We also thank GW Pharmaceuticals for the use of their
data and continued support.
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